Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 20 articles: HTML format

Single Articles

March 2023
1. SARTOR O
   Localized Prostate Cancer - Then and Now.
   N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
   PubMed    
   
   
   
2. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
   Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
   N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
   PubMed     Abstract available
   
   
   February 2023
3. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
   Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
   N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
   PubMed     Abstract available
   
   
   
4. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
   Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
   N Engl J Med. 2023;388:660-662.
   PubMed    
   
   
   December 2022
5. GULATI R
   Reducing Prostate Cancer Overdiagnosis.
   N Engl J Med. 2022;387:2187-2188.
   PubMed    
   
   
   
6. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
   Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
   N Engl J Med. 2022;387:2126-2137.
   PubMed     Abstract available
   
   
   September 2022
7. 
   Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
   N Engl J Med. 2022;387:860.
   PubMed    
   
   
   June 2022
8. SMITH MR
   Darolutamide in Metastatic Prostate Cancer. Reply.
   N Engl J Med. 2022;386:2345.
   PubMed    
   
   
   
9. BOWLING GC, Dimitrakoff JD
   Darolutamide in Metastatic Prostate Cancer.
   N Engl J Med. 2022;386:2344.
   PubMed    
   
   
   
10. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    
    
    
    February 2022
11. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available
    
    
    December 2021
12. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    
    
    
    
13. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    
    
    
    
14. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    
    
    
    
15. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    
    
    
    November 2021
16. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    
    
    
    
17. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    
    
    
    
18. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    
    
    
    July 2021
19. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available
    
    
    June 2021
20. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: